<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02025179</url>
  </required_header>
  <id_info>
    <org_study_id>A1195</org_study_id>
    <nct_id>NCT02025179</nct_id>
  </id_info>
  <brief_title>12 Month Extension Study of the Effect of Teriparatide on Bone in People With Chronic Spinal Cord Injury (SCI)</brief_title>
  <official_title>12 Month Open-Label Extension Study of the Effect of Teriparatide on Bone in People With Chronic SCI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if a second year of exposure to teriparatide in
      both subjects that received a year of teriparatide or teriparatide-placebo will result in a
      greater increase in bone mass density (BMD) compared to that seen in a single year's
      treatment.

      This study will also investigate 1) if a second year of teriparatide therapy will increase
      bone strength in people with chronic spinal cord injury (SCI) who previously received a year
      of teriparatide or teriparatide-placebo, 2) the number of participants with adverse events
      from teriparatide, and 3) the effects of teriparatide on serum markers of bone metabolism.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This extension study will only enroll individuals who have completed one year of treatment in
      the parent protocol &quot;Effect of Teriparatide, Vibration and the Combination on Bone Mass and
      Bone Architecture in Chronic Spinal Cord Injury (NCT01225055)&quot;. This study will allow those
      individuals who received Teriparatide (20ug/day) and vibration (10 min/day) during the parent
      study to be treated for a second year and will allow those individuals who received
      teriparatide-placebo to have the opportunity to have a full year of teriparatide therapy.
      This study will determine if two years of exposure to teriparatide will result in a greater
      increase in Bone Mass Density (BMD) than that seen after a single year's treatment. Subjects
      will be evaluated at 6 and 12 months after initiating treatment with measurement of bone
      density as well as bone markers of formation and resorption.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 2013</start_date>
  <completion_date type="Actual">August 14, 2015</completion_date>
  <primary_completion_date type="Actual">August 14, 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bone Mineral Density (BMD) of the Total Hip as Assessed by Dual-energy X-ray Absorptiometry (DXA)</measure>
    <time_frame>Baseline to 24 months</time_frame>
    <description>The mean percent change in BMD of the total hip after 24 months of treatment. Arms/Groups (3) below are divided into the Arms/Groups these subjects were in the parent protocol (NCT01225055) for the 12 month duration of this previous study. These subjects were then enrolled in this 12 month extension study (NCT02025179) and all received Teriparatide and vibration for 12 months as described in the protocol section. The &quot;Baseline&quot; refers to the baseline at the parent protocol (NCT01225055). The &quot;24 months&quot; refers to period after the completion of the 12 month parent protocol (NCT01225055) and this 12 month extension study (NCT02025179).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>C-terminal Telopeptide</measure>
    <time_frame>Baseline to 24 Months</time_frame>
    <description>The mean percent change in C-terminal telopeptide from baseline after 24 months of treatment. Arms/Groups (3) below are divided into the Arms/Groups these subjects were in the parent protocol (NCT01225055) for the 12 month duration of this previous study. These subjects were then enrolled in this 12 month extension study (NCT02025179) and all received Teriparatide and vibration for 12 months as described in the protocol section. The &quot;Baseline&quot; refers to the baseline at the parent protocol (NCT01225055). The &quot;24 months&quot; refers to period after the completion of the 12 month parent protocol (NCT01225055) and this 12 month extension study (NCT02025179).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Mineral Density (BMD) by DXA at the Lumbar Spine</measure>
    <time_frame>Baseline to 24 Months</time_frame>
    <description>The mean percent change in BMD at the lumbar spine from baseline after 24 months of treatment. Arms/Groups (3) below are divided into the Arms/Groups these subjects were in the parent protocol (NCT01225055) for the 12 month duration of this previous study. These subjects were then enrolled in this 12 month extension study (NCT02025179) and all received Teriparatide and vibration for 12 months as described in the protocol section. The &quot;Baseline&quot; refers to the baseline at the parent protocol (NCT01225055). The &quot;24 months&quot; refers to period after the completion of the 12 month parent protocol (NCT01225055) and this 12 month extension study (NCT02025179).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone Mineral Density (BMD) by DXA at Femoral Neck</measure>
    <time_frame>Baseline to 24 Months</time_frame>
    <description>The mean percent change in BMD of the femoral neck after 24 months of treatment. Arms/Groups (3) below are divided into the Arms/Groups these subjects were in the parent protocol (NCT01225055) for the 12 month duration of this previous study. These subjects were then enrolled in this 12 month extension study (NCT02025179) and all received Teriparatide and vibration for 12 months as described in the protocol section. The &quot;Baseline&quot; refers to the baseline at the parent protocol (NCT01225055). The &quot;24 months&quot; refers to period after the completion of the 12 month parent protocol (NCT01225055) and this 12 month extension study (NCT02025179).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amino-terminal Propeptide of Type 1 Collagen</measure>
    <time_frame>Baseline to 24 Months</time_frame>
    <description>The mean percent change in Amino-terminal of type 1 collagen from baseline after 24 months of treatment. Arms/Groups (3) below are divided into the Arms/Groups these subjects were in the parent protocol (NCT01225055) for the 12 month duration of this previous study. These subjects were then enrolled in this 12 month extension study (NCT02025179) and all received Teriparatide and vibration for 12 months as described in the protocol section. The &quot;Baseline&quot; refers to the baseline at the parent protocol (NCT01225055). The &quot;24 months&quot; refers to period after the completion of the 12 month parent protocol (NCT01225055) and this 12 month extension study (NCT02025179).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bone-specific Alkaline Phosphatase</measure>
    <time_frame>Baseline to 24 Months</time_frame>
    <description>The mean percent change in Bone-specific alkaline phosphatase from baseline after 24 months of treatment. Arms/Groups (3) below are divided into the Arms/Groups these subjects were in the parent protocol (NCT01225055) for the 12 month duration of this previous study. These subjects were then enrolled in this 12 month extension study (NCT02025179) and all received Teriparatide and vibration for 12 months as described in the protocol section. The &quot;Baseline&quot; refers to the baseline at the parent protocol (NCT01225055). The &quot;24 months&quot; refers to period after the completion of the 12 month parent protocol (NCT01225055) and this 12 month extension study (NCT02025179).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Spinal Cord Injury</condition>
  <condition>Bone Loss</condition>
  <condition>Osteoporosis</condition>
  <arm_group>
    <arm_group_label>Teriparatide and vibration</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Experimental: Teriparatide and vibration
Drug: Teriparatide (Forteo) 20 ug daily Sub-Q over 12 months
Device: Vibration 10 min/day for 12 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriparatide</intervention_name>
    <description>Teriparatide 20 ug daily Sub-Q over 12 months</description>
    <arm_group_label>Teriparatide and vibration</arm_group_label>
    <other_name>Forteo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vibration</intervention_name>
    <description>Vibration 10 min/day for 12 months</description>
    <arm_group_label>Teriparatide and vibration</arm_group_label>
    <other_name>Soloflex Whole Body Vibration platform</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Enrollment in, and completion of one year of treatment, in protocol &quot;Effect of
             Teriparatide, Vibration and the Combination on Bone Mass and Bone Architecture in
             Chronic Spinal Cord Injury&quot;.

          -  Adherence rate for teriparatide use of ≥60%.

          -  Women of child-bearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control; abstinence) prior to study entry, for
             the duration of study participation, and for 90 days following completion of therapy.
             Should a woman become pregnant or suspect she is pregnant while participating in this
             study, she should inform her treating physician immediately.

          -  A female of child-bearing potential is any woman (regardless of sexual orientation,
             having undergone a tubal ligation, or remaining celibate by choice) who meets the
             following criteria:

               -  Has not undergone a hysterectomy or bilateral oophorectomy; or

               -  Has not been naturally postmenopausal for at least 12 consecutive months (i.e.,
                  has had menses at any time in the preceding 12 consecutive months).

          -  Ability to understand and the willingness to sign a written informed consent.

        Exclusion Criteria:

          -  Individuals who could not tolerate teriparatide treatment.

          -  Individuals who will not be able to return for all study visits.

          -  Patients may not be receiving any other investigational agents.

          -  Other medical conditions that in the opinion of the investigator would preclude the
             subject from completing the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas J Schnitzer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Northwestern University Feinberg School of Medicine</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>December 21, 2013</study_first_submitted>
  <study_first_submitted_qc>December 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2013</study_first_posted>
  <results_first_submitted>May 10, 2018</results_first_submitted>
  <results_first_submitted_qc>August 28, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">September 25, 2018</results_first_posted>
  <last_update_submitted>August 28, 2018</last_update_submitted>
  <last_update_submitted_qc>August 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Thomas J. Schnitzer</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Teriparatide</keyword>
  <keyword>Osteoporosis</keyword>
  <keyword>Spinal Cord Injury</keyword>
  <keyword>Bone Diseases</keyword>
  <keyword>Metabolic Bone Diseases</keyword>
  <keyword>Musculoskeletal Diseases</keyword>
  <keyword>Spinal Cord Diseases</keyword>
  <keyword>Central Nervous System Diseases</keyword>
  <keyword>Nervous System Diseases</keyword>
  <keyword>Nervous System</keyword>
  <keyword>Wounds and Injuries</keyword>
  <keyword>Bone Density Conservation Agents</keyword>
  <keyword>Physiological Effects of Drugs</keyword>
  <keyword>Pharmacologic Actions</keyword>
  <keyword>Vibration</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Teriparatide</title>
          <description>Experimental: Teriparatide and vibration
Drug: Teriparatide (Forteo) 20 ug daily Sub-Q over 12 months
Device: Vibration 10 min/day for 12 months
Completed in previously enrolled study (STU00033380),
Teriparatide alone with sham vibration
Teriparatide: 20 ug daily over 12 months</description>
        </group>
        <group group_id="P2">
          <title>Vibration</title>
          <description>Experimental: Teriparatide and vibration
Drug: Teriparatide (Forteo) 20 ug daily Sub-Q over 12 months
Device: Vibration 10 min/day for 12 months
Completed in previously enrolled study (STU00033380),
Vibration alone with placebo-teriparatide
vibration: 10 min/day for 12 months</description>
        </group>
        <group group_id="P3">
          <title>Teriparatide and Vibration</title>
          <description>Experimental: Teriparatide and vibration
Drug: Teriparatide (Forteo) 20 ug daily Sub-Q over 12 months
Device: Vibration 10 min/day for 12 months
Completed in previously enrolled study (STU00033380),
Teriparatide with vibration applied in conjunction
Teriparatide: 20 ug daily over 12 months
vibration: 10 min/day for 12 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Teriparatide</title>
          <description>Experimental: Teriparatide and vibration
Drug: Teriparatide (Forteo) 20 ug daily Sub-Q over 12 months
Device: Vibration 10 min/day for 12 months
Completed in previously enrolled study (STU00033380),
Teriparatide alone with sham vibration
Teriparatide: 20 ug daily over 12 months</description>
        </group>
        <group group_id="B2">
          <title>Vibration</title>
          <description>Experimental: Teriparatide and vibration
Drug: Teriparatide (Forteo) 20 ug daily Sub-Q over 12 months
Device: Vibration 10 min/day for 12 months
Completed in previously enrolled study (STU00033380),
Vibration alone with placebo-teriparatide
vibration: 10 min/day for 12 months</description>
        </group>
        <group group_id="B3">
          <title>Teriparatide and Vibration</title>
          <description>Experimental: Teriparatide and vibration
Drug: Teriparatide (Forteo) 20 ug daily Sub-Q over 12 months
Device: Vibration 10 min/day for 12 months
Completed in previously enrolled study (STU00033380),
Teriparatide with vibration applied in conjunction
Teriparatide: 20 ug daily over 12 months
vibration: 10 min/day for 12 months</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="8"/>
            <count group_id="B4" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.2" lower_limit="21.1" upper_limit="65.3"/>
                    <measurement group_id="B2" value="38.0" lower_limit="22.2" upper_limit="62.7"/>
                    <measurement group_id="B3" value="41.7" lower_limit="22.8" upper_limit="64.9"/>
                    <measurement group_id="B4" value="40.5" lower_limit="21.1" upper_limit="65.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>American Spinal Injury Association (ASIA) Impairment Scale</title>
          <description>ASIA impairment scale describes a person’s functional impairment as a result of their spinal cord injury.
A = Complete. No motor or sensory function in the lowest sacral spine segment (S4-5).
B = Sensory Incomplete. Sensory function below the neurological level of injury (NLI) and in S4-S5, no motor function below NLI.
C = Motor Incomplete. Motor function is preserved below NLI and more than half of the key muscle groups below NLI have a muscle grade &lt; 3.
D = Motor Incomplete. Motor function is preserved below NLI and at least half of the key muscle groups below NLI have a muscle grade 3.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>ASIA A (Complete Injury)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ASIA B (Sensory Incomplete Injury)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ASIA C (Motor Incomplete Injury)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>ASIA D (Motor Incomplete Injury)</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Bone Mineral Density (BMD) of the Total Hip as Assessed by Dual-energy X-ray Absorptiometry (DXA)</title>
        <description>The mean percent change in BMD of the total hip after 24 months of treatment. Arms/Groups (3) below are divided into the Arms/Groups these subjects were in the parent protocol (NCT01225055) for the 12 month duration of this previous study. These subjects were then enrolled in this 12 month extension study (NCT02025179) and all received Teriparatide and vibration for 12 months as described in the protocol section. The &quot;Baseline&quot; refers to the baseline at the parent protocol (NCT01225055). The &quot;24 months&quot; refers to period after the completion of the 12 month parent protocol (NCT01225055) and this 12 month extension study (NCT02025179).</description>
        <time_frame>Baseline to 24 months</time_frame>
        <population>One subject in &quot;Teriparatide and vibration&quot; group was lost to follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Teriparatide</title>
            <description>Experimental: Teriparatide and vibration
Drug: Teriparatide (Forteo) 20 ug daily Sub-Q over 12 months
Device: Vibration 10 min/day for 12 months
Completed in previously enrolled study (STU00033380),
Teriparatide alone with sham vibration
Teriparatide: 20 ug daily over 12 months</description>
          </group>
          <group group_id="O2">
            <title>Vibration</title>
            <description>Experimental: Teriparatide and vibration
Drug: Teriparatide (Forteo) 20 ug daily Sub-Q over 12 months
Device: Vibration 10 min/day for 12 months
Completed in previously enrolled study (STU00033380),
Vibration alone with placebo-teriparatide
vibration: 10 min/day for 12 months</description>
          </group>
          <group group_id="O3">
            <title>Teriparatide and Vibration</title>
            <description>Experimental: Teriparatide and vibration
Drug: Teriparatide (Forteo) 20 ug daily Sub-Q over 12 months
Device: Vibration 10 min/day for 12 months
Completed in previously enrolled study (STU00033380),
Teriparatide with vibration applied in conjunction
Teriparatide: 20 ug daily over 12 months
vibration: 10 min/day for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Mineral Density (BMD) of the Total Hip as Assessed by Dual-energy X-ray Absorptiometry (DXA)</title>
          <description>The mean percent change in BMD of the total hip after 24 months of treatment. Arms/Groups (3) below are divided into the Arms/Groups these subjects were in the parent protocol (NCT01225055) for the 12 month duration of this previous study. These subjects were then enrolled in this 12 month extension study (NCT02025179) and all received Teriparatide and vibration for 12 months as described in the protocol section. The &quot;Baseline&quot; refers to the baseline at the parent protocol (NCT01225055). The &quot;24 months&quot; refers to period after the completion of the 12 month parent protocol (NCT01225055) and this 12 month extension study (NCT02025179).</description>
          <population>One subject in &quot;Teriparatide and vibration&quot; group was lost to follow-up</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.73" lower_limit="3.37" upper_limit="10.1"/>
                    <measurement group_id="O2" value="-0.34" lower_limit="-3.50" upper_limit="2.82"/>
                    <measurement group_id="O3" value="4.24" lower_limit="0.37" upper_limit="8.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C-terminal Telopeptide</title>
        <description>The mean percent change in C-terminal telopeptide from baseline after 24 months of treatment. Arms/Groups (3) below are divided into the Arms/Groups these subjects were in the parent protocol (NCT01225055) for the 12 month duration of this previous study. These subjects were then enrolled in this 12 month extension study (NCT02025179) and all received Teriparatide and vibration for 12 months as described in the protocol section. The &quot;Baseline&quot; refers to the baseline at the parent protocol (NCT01225055). The &quot;24 months&quot; refers to period after the completion of the 12 month parent protocol (NCT01225055) and this 12 month extension study (NCT02025179).</description>
        <time_frame>Baseline to 24 Months</time_frame>
        <population>One subject in &quot;Teriparatide and vibration&quot; group was lost to follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Teriparatide</title>
            <description>Experimental: Teriparatide and vibration
Drug: Teriparatide (Forteo) 20 ug daily Sub-Q over 12 months
Device: Vibration 10 min/day for 12 months
Completed in previously enrolled study (STU00033380),
Teriparatide alone with sham vibration
Teriparatide: 20 ug daily over 12 months</description>
          </group>
          <group group_id="O2">
            <title>Vibration</title>
            <description>Experimental: Teriparatide and vibration
Drug: Teriparatide (Forteo) 20 ug daily Sub-Q over 12 months
Device: Vibration 10 min/day for 12 months
Completed in previously enrolled study (STU00033380),
Vibration alone with placebo-teriparatide
vibration: 10 min/day for 12 months</description>
          </group>
          <group group_id="O3">
            <title>Teriparatide and Vibration</title>
            <description>Experimental: Teriparatide and vibration
Drug: Teriparatide (Forteo) 20 ug daily Sub-Q over 12 months
Device: Vibration 10 min/day for 12 months
Completed in previously enrolled study (STU00033380),
Teriparatide with vibration applied in conjunction
Teriparatide: 20 ug daily over 12 months
vibration: 10 min/day for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>C-terminal Telopeptide</title>
          <description>The mean percent change in C-terminal telopeptide from baseline after 24 months of treatment. Arms/Groups (3) below are divided into the Arms/Groups these subjects were in the parent protocol (NCT01225055) for the 12 month duration of this previous study. These subjects were then enrolled in this 12 month extension study (NCT02025179) and all received Teriparatide and vibration for 12 months as described in the protocol section. The &quot;Baseline&quot; refers to the baseline at the parent protocol (NCT01225055). The &quot;24 months&quot; refers to period after the completion of the 12 month parent protocol (NCT01225055) and this 12 month extension study (NCT02025179).</description>
          <population>One subject in &quot;Teriparatide and vibration&quot; group was lost to follow-up</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-19.8" lower_limit="-69.0" upper_limit="29.5"/>
                    <measurement group_id="O2" value="-14.8" lower_limit="-61.2" upper_limit="31.6"/>
                    <measurement group_id="O3" value="-2.12" lower_limit="-54.8" upper_limit="50.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Mineral Density (BMD) by DXA at the Lumbar Spine</title>
        <description>The mean percent change in BMD at the lumbar spine from baseline after 24 months of treatment. Arms/Groups (3) below are divided into the Arms/Groups these subjects were in the parent protocol (NCT01225055) for the 12 month duration of this previous study. These subjects were then enrolled in this 12 month extension study (NCT02025179) and all received Teriparatide and vibration for 12 months as described in the protocol section. The &quot;Baseline&quot; refers to the baseline at the parent protocol (NCT01225055). The &quot;24 months&quot; refers to period after the completion of the 12 month parent protocol (NCT01225055) and this 12 month extension study (NCT02025179).</description>
        <time_frame>Baseline to 24 Months</time_frame>
        <population>One subject in &quot;Teriparatide and vibration&quot; group was lost to follow-up. Another subject in &quot;Teriparatide and vibration&quot; spine could not be analyzed due to a baclofen pump.</population>
        <group_list>
          <group group_id="O1">
            <title>Teriparatide</title>
            <description>Experimental: Teriparatide and vibration
Drug: Teriparatide (Forteo) 20 ug daily Sub-Q over 12 months
Device: Vibration 10 min/day for 12 months
Completed in previously enrolled study (STU00033380),
Teriparatide alone with sham vibration
Teriparatide: 20 ug daily over 12 months</description>
          </group>
          <group group_id="O2">
            <title>Vibration</title>
            <description>Experimental: Teriparatide and vibration
Drug: Teriparatide (Forteo) 20 ug daily Sub-Q over 12 months
Device: Vibration 10 min/day for 12 months
Completed in previously enrolled study (STU00033380),
Vibration alone with placebo-teriparatide
vibration: 10 min/day for 12 months</description>
          </group>
          <group group_id="O3">
            <title>Teriparatide and Vibration</title>
            <description>Experimental: Teriparatide and vibration
Drug: Teriparatide (Forteo) 20 ug daily Sub-Q over 12 months
Device: Vibration 10 min/day for 12 months
Completed in previously enrolled study (STU00033380),
Teriparatide with vibration applied in conjunction
Teriparatide: 20 ug daily over 12 months
vibration: 10 min/day for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Mineral Density (BMD) by DXA at the Lumbar Spine</title>
          <description>The mean percent change in BMD at the lumbar spine from baseline after 24 months of treatment. Arms/Groups (3) below are divided into the Arms/Groups these subjects were in the parent protocol (NCT01225055) for the 12 month duration of this previous study. These subjects were then enrolled in this 12 month extension study (NCT02025179) and all received Teriparatide and vibration for 12 months as described in the protocol section. The &quot;Baseline&quot; refers to the baseline at the parent protocol (NCT01225055). The &quot;24 months&quot; refers to period after the completion of the 12 month parent protocol (NCT01225055) and this 12 month extension study (NCT02025179).</description>
          <population>One subject in &quot;Teriparatide and vibration&quot; group was lost to follow-up. Another subject in &quot;Teriparatide and vibration&quot; spine could not be analyzed due to a baclofen pump.</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" lower_limit="11.0" upper_limit="17.8"/>
                    <measurement group_id="O2" value="7.05" lower_limit="3.87" upper_limit="10.2"/>
                    <measurement group_id="O3" value="8.98" lower_limit="5.08" upper_limit="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone Mineral Density (BMD) by DXA at Femoral Neck</title>
        <description>The mean percent change in BMD of the femoral neck after 24 months of treatment. Arms/Groups (3) below are divided into the Arms/Groups these subjects were in the parent protocol (NCT01225055) for the 12 month duration of this previous study. These subjects were then enrolled in this 12 month extension study (NCT02025179) and all received Teriparatide and vibration for 12 months as described in the protocol section. The &quot;Baseline&quot; refers to the baseline at the parent protocol (NCT01225055). The &quot;24 months&quot; refers to period after the completion of the 12 month parent protocol (NCT01225055) and this 12 month extension study (NCT02025179).</description>
        <time_frame>Baseline to 24 Months</time_frame>
        <population>One subject in &quot;Teriparatide and vibration&quot; group was lost to follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Teriparatide</title>
            <description>Experimental: Teriparatide and vibration
Drug: Teriparatide (Forteo) 20 ug daily Sub-Q over 12 months
Device: Vibration 10 min/day for 12 months
Completed in previously enrolled study (STU00033380),
Teriparatide alone with sham vibration
Teriparatide: 20 ug daily over 12 months</description>
          </group>
          <group group_id="O2">
            <title>Vibration</title>
            <description>Experimental: Teriparatide and vibration
Drug: Teriparatide (Forteo) 20 ug daily Sub-Q over 12 months
Device: Vibration 10 min/day for 12 months
Completed in previously enrolled study (STU00033380),
Vibration alone with placebo-teriparatide
vibration: 10 min/day for 12 months</description>
          </group>
          <group group_id="O3">
            <title>Teriparatide and Vibration</title>
            <description>Experimental: Teriparatide and vibration
Drug: Teriparatide (Forteo) 20 ug daily Sub-Q over 12 months
Device: Vibration 10 min/day for 12 months
Completed in previously enrolled study (STU00033380),
Teriparatide with vibration applied in conjunction
Teriparatide: 20 ug daily over 12 months
vibration: 10 min/day for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Bone Mineral Density (BMD) by DXA at Femoral Neck</title>
          <description>The mean percent change in BMD of the femoral neck after 24 months of treatment. Arms/Groups (3) below are divided into the Arms/Groups these subjects were in the parent protocol (NCT01225055) for the 12 month duration of this previous study. These subjects were then enrolled in this 12 month extension study (NCT02025179) and all received Teriparatide and vibration for 12 months as described in the protocol section. The &quot;Baseline&quot; refers to the baseline at the parent protocol (NCT01225055). The &quot;24 months&quot; refers to period after the completion of the 12 month parent protocol (NCT01225055) and this 12 month extension study (NCT02025179).</description>
          <population>One subject in &quot;Teriparatide and vibration&quot; group was lost to follow-up</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.73" lower_limit="-2.81" upper_limit="8.26"/>
                    <measurement group_id="O2" value="-0.06" lower_limit="-5.28" upper_limit="5.16"/>
                    <measurement group_id="O3" value="4.71" lower_limit="-1.20" upper_limit="10.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amino-terminal Propeptide of Type 1 Collagen</title>
        <description>The mean percent change in Amino-terminal of type 1 collagen from baseline after 24 months of treatment. Arms/Groups (3) below are divided into the Arms/Groups these subjects were in the parent protocol (NCT01225055) for the 12 month duration of this previous study. These subjects were then enrolled in this 12 month extension study (NCT02025179) and all received Teriparatide and vibration for 12 months as described in the protocol section. The &quot;Baseline&quot; refers to the baseline at the parent protocol (NCT01225055). The &quot;24 months&quot; refers to period after the completion of the 12 month parent protocol (NCT01225055) and this 12 month extension study (NCT02025179).</description>
        <time_frame>Baseline to 24 Months</time_frame>
        <population>One subject in &quot;Teriparatide and vibration&quot; group was lost to follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Teriparatide</title>
            <description>Experimental: Teriparatide and vibration
Drug: Teriparatide (Forteo) 20 ug daily Sub-Q over 12 months
Device: Vibration 10 min/day for 12 months
Completed in previously enrolled study (STU00033380),
Teriparatide alone with sham vibration
Teriparatide: 20 ug daily over 12 months</description>
          </group>
          <group group_id="O2">
            <title>Vibration</title>
            <description>Experimental: Teriparatide and vibration
Drug: Teriparatide (Forteo) 20 ug daily Sub-Q over 12 months
Device: Vibration 10 min/day for 12 months
Completed in previously enrolled study (STU00033380),
Vibration alone with placebo-teriparatide
vibration: 10 min/day for 12 months</description>
          </group>
          <group group_id="O3">
            <title>Teriparatide and Vibration</title>
            <description>Experimental: Teriparatide and vibration
Drug: Teriparatide (Forteo) 20 ug daily Sub-Q over 12 months
Device: Vibration 10 min/day for 12 months
Completed in previously enrolled study (STU00033380),
Teriparatide with vibration applied in conjunction
Teriparatide: 20 ug daily over 12 months
vibration: 10 min/day for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Amino-terminal Propeptide of Type 1 Collagen</title>
          <description>The mean percent change in Amino-terminal of type 1 collagen from baseline after 24 months of treatment. Arms/Groups (3) below are divided into the Arms/Groups these subjects were in the parent protocol (NCT01225055) for the 12 month duration of this previous study. These subjects were then enrolled in this 12 month extension study (NCT02025179) and all received Teriparatide and vibration for 12 months as described in the protocol section. The &quot;Baseline&quot; refers to the baseline at the parent protocol (NCT01225055). The &quot;24 months&quot; refers to period after the completion of the 12 month parent protocol (NCT01225055) and this 12 month extension study (NCT02025179).</description>
          <population>One subject in &quot;Teriparatide and vibration&quot; group was lost to follow-up</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="102" lower_limit="73" upper_limit="132"/>
                    <measurement group_id="O2" value="104" lower_limit="76.6" upper_limit="132"/>
                    <measurement group_id="O3" value="58" lower_limit="26.6" upper_limit="89.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Bone-specific Alkaline Phosphatase</title>
        <description>The mean percent change in Bone-specific alkaline phosphatase from baseline after 24 months of treatment. Arms/Groups (3) below are divided into the Arms/Groups these subjects were in the parent protocol (NCT01225055) for the 12 month duration of this previous study. These subjects were then enrolled in this 12 month extension study (NCT02025179) and all received Teriparatide and vibration for 12 months as described in the protocol section. The &quot;Baseline&quot; refers to the baseline at the parent protocol (NCT01225055). The &quot;24 months&quot; refers to period after the completion of the 12 month parent protocol (NCT01225055) and this 12 month extension study (NCT02025179).</description>
        <time_frame>Baseline to 24 Months</time_frame>
        <population>One subject in &quot;Teriparatide and vibration&quot; group was lost to follow-up</population>
        <group_list>
          <group group_id="O1">
            <title>Teriparatide</title>
            <description>Experimental: Teriparatide and vibration
Drug: Teriparatide (Forteo) 20 ug daily Sub-Q over 12 months
Device: Vibration 10 min/day for 12 months
Completed in previously enrolled study (STU00033380),
Teriparatide alone with sham vibration
Teriparatide: 20 ug daily over 12 months</description>
          </group>
          <group group_id="O2">
            <title>Vibration</title>
            <description>Experimental: Teriparatide and vibration
Drug: Teriparatide (Forteo) 20 ug daily Sub-Q over 12 months
Device: Vibration 10 min/day for 12 months
Completed in previously enrolled study (STU00033380),
Vibration alone with placebo-teriparatide
vibration: 10 min/day for 12 months</description>
          </group>
          <group group_id="O3">
            <title>Teriparatide and Vibration</title>
            <description>Experimental: Teriparatide and vibration
Drug: Teriparatide (Forteo) 20 ug daily Sub-Q over 12 months
Device: Vibration 10 min/day for 12 months
Completed in previously enrolled study (STU00033380),
Teriparatide with vibration applied in conjunction
Teriparatide: 20 ug daily over 12 months
vibration: 10 min/day for 12 months</description>
          </group>
        </group_list>
        <measure>
          <title>Bone-specific Alkaline Phosphatase</title>
          <description>The mean percent change in Bone-specific alkaline phosphatase from baseline after 24 months of treatment. Arms/Groups (3) below are divided into the Arms/Groups these subjects were in the parent protocol (NCT01225055) for the 12 month duration of this previous study. These subjects were then enrolled in this 12 month extension study (NCT02025179) and all received Teriparatide and vibration for 12 months as described in the protocol section. The &quot;Baseline&quot; refers to the baseline at the parent protocol (NCT01225055). The &quot;24 months&quot; refers to period after the completion of the 12 month parent protocol (NCT01225055) and this 12 month extension study (NCT02025179).</description>
          <population>One subject in &quot;Teriparatide and vibration&quot; group was lost to follow-up</population>
          <units>Percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" lower_limit="9.04" upper_limit="14.0"/>
                    <measurement group_id="O2" value="12.6" lower_limit="10.3" upper_limit="14.9"/>
                    <measurement group_id="O3" value="10.9" lower_limit="8.30" upper_limit="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 months</time_frame>
      <desc>One subject in &quot;Teriparatide and vibration&quot; group was lost to follow-up. Arms/Groups (3) below are divided into the Arms/Groups these subjects were in the parent protocol (NCT01225055) for the 12 month duration of this previous study. These subjects were then enrolled in this 12 month extension study (NCT02025179) and all received Teriparatide and vibration for 12 months as described in the protocol section.</desc>
      <group_list>
        <group group_id="E1">
          <title>Teriparatide</title>
          <description>Experimental: Teriparatide and vibration
Drug: Teriparatide (Forteo) 20 ug daily Sub-Q over 12 months
Device: Vibration 10 min/day for 12 months
Completed in previously enrolled study (STU00033380),
Teriparatide alone with sham vibration
Teriparatide: 20 ug daily over 12 months</description>
        </group>
        <group group_id="E2">
          <title>Vibration</title>
          <description>Experimental: Teriparatide and vibration
Drug: Teriparatide (Forteo) 20 ug daily Sub-Q over 12 months
Device: Vibration 10 min/day for 12 months
Completed in previously enrolled study (STU00033380),
Vibration alone with placebo-teriparatide
vibration: 10 min/day for 12 months</description>
        </group>
        <group group_id="E3">
          <title>Teriparatide and Vibration</title>
          <description>Experimental: Teriparatide and vibration
Drug: Teriparatide (Forteo) 20 ug daily Sub-Q over 12 months
Device: Vibration 10 min/day for 12 months
Completed in previously enrolled study (STU00033380),
Teriparatide with vibration applied in conjunction
Teriparatide: 20 ug daily over 12 months
vibration: 10 min/day for 12 months</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Kidney Stone</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="9"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic Reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Allergies</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cold/Flu</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Cut</sub_title>
                <description>Cut Tip of Left Thumb</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Lower extremity fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Toe wound</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="6" subjects_affected="3" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pinched nerve</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dry scalp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pressure sore</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="9"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Thomas Schnitzer</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-503-2315</phone>
      <email>tjs@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

